hki

HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM), effectively suppressing EGFR autophosphorylation (at Y1068), as well as AKT and MAPK phosphorylation.

HKI-357 dimaleate is an irreversible dual inhibitor of EGFR and ERBB2. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.

KHKI-01215 is an effective NUAK2 inhibitor with anticancer activity, inhibiting the proliferation of SW480 cancer cells and inducing apoptosis in SW480 cells. KHKI-01215 is used for cancer research.

HKI12134085 (compound 3), an orally administered nitrobenzothiazinone (BTZ) derivative, demonstrates antibacterial efficacy against Mycobacterium tuberculosis. This compound exhibits significant in vivo inhibitory potency within a BALB c mouse model of Mycobacterium tuberculosis infection [1].

KHKI-01128 is a NUAK2 inhibitor with an IC50 of 0.024 μM. It demonstrates effective anticancer activity against SW480 colorectal cancer cells.

Neratinib (HKI-272) (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor for HER2 and EGFR (IC50: 59 92 nM), respectively.

Neratinib maleate (HKI-272 maleate) is an irreversible, orally active and highly selective inhibitor of HER2 and EGFR with IC50 values of 59 nM and 92 nM, respectively.Neratinib maleate has antitumor activity and can be used to treat gastrointestinal, respiratory, genitourinary, and cutaneous and musculoskeletal diseases, and can be used to study breast and prostate cancer. used in the study of breast and prostate cancer.

MDL-102234 is an adenosine A1 receptor antagonist.

HBY-793 is an HIV-1 proteinase inhibitor.

Ampullosporin A is a peptaibol-type polypeptide isolated from the fungus Sepedonium ampullosporum (HKI-0053), exhibiting neuromodulatory activity. It inhibits hyperactivity induced by the NMDA receptor antagonist MK-801 and ameliorates social behavior abnormalities caused by subchronic ketamine treatment. Ampullosporin A modulates glutamate receptor activity without affecting dopamine D1 and D2 receptors.